Clinical trials
High Risk clinical trials
Below are recruiting high risk clinical trials, each written for real people, not researchers. We’re tracking 922 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05806515RecruitingPhase 2
Carboplatin before surgery for high-risk BRCA prostate cancer
This trial tests giving the chemotherapy drug carboplatin before surgery to treat people with high-risk prostate cancer and an inherited BRCA1 or BRCA2 gene change. The goal is to shrink or control the cancer before an operation and improve outcomes.
Anchorage, AlaskaAges 18 years+ - NCT05800366RecruitingPhase 2
Testing glofitamab plus polatuzumab for high-risk diffuse lymphoma
This Phase 2 study tests two medicines—glofitamab and polatuzumab—together with chemotherapy to treat newly diagnosed, high-risk diffuse large B-cell lymphoma (DLBCL) that has the CD20 marker. It aims to improve how well the lymphoma responds and how long responses last.
Miami, FloridaAges 18 years+ - NCT05765175Recruiting
Radioablation versus repeat ablation for hard-to-treat VT
This trial compares a heart procedure using targeted radiation (called radioablation) to a repeat catheter ablation for people with high-risk, hard-to-control ventricular tachycardia (VT). It aims to find which approach is safer and works better after standard ablation and amiodarone have not stopped the abnormal rhythm.
Los Angeles, CaliforniaAges 18 years+ - NCT05777512Recruiting
Comparing feeding tube placement to improve breathing in preterm infants
This study tests whether placing a feeding tube past the stomach (postpyloric) can help very premature babies with ongoing lung problems breathe better. Infants born before 32 weeks who still need breathing support may join.
Boston, MassachusettsAges birth–1 year - NCT05775471RecruitingPhase 2
Check PD-1 plus enfortumab after kidney-urine-duct surgery
This Phase 2 study tests giving pembrolizumab (an immune therapy) and enfortumab vedotin (an antibody-drug medicine) before and after surgery to remove high-risk upper urinary tract cancer. The goal is to lower the chance the cancer comes back.
Los Angeles, CaliforniaAges 18 years+ - NCT05776979RecruitingPhase 2
Isatuximab plus lenalidomide after transplant for high-risk myeloma
This Phase 2 trial tests whether adding isatuximab and lenalidomide as long-term treatment after stem cell transplant can help keep high-risk multiple myeloma under control. It may help some people reduce the chance of the disease coming back after transplant.
Houston, TexasAges 18–72 - NCT05712200RecruitingPhase 3
Abelacimab for atrial fibrillation when blood thinners aren’t suitable
This Phase 3 study tests whether abelacimab can prevent stroke and other blood-clot problems in people with atrial fibrillation (or atrial flutter) who cannot safely take usual mouth blood thinners. It also looks at safety, especially bleeding risk.
Birmingham, AlabamaAges 65 years+ - NCT05722873Recruiting
Study intermittent fasting and its effects on metabolism
This study looks at how intermittent fasting affects your body's “metabolism” (how you use food and manage blood sugar/fats). It may help researchers understand whether this eating pattern changes metabolic health in people at higher risk for type 2 diabetes.
Pittsburgh, PennsylvaniaAges 21–45 - NCT05722405RecruitingPhase 4
Ixazomib plus lenalidomide compared to ixazomib alone for myeloma maintenance
This trial studies whether adding low-dose lenalidomide to ixazomib can help keep high-risk multiple myeloma from coming back after initial treatment. It may help prolong the time before the disease worsens, while also checking side effects.
Hangzhou, ZhejiangAges 18–80 - NCT05727761RecruitingPhase 2
Pioglitazone plus metformin for high-risk mouth lesions
This trial studies whether a two-medicine diabetes drug combination can reduce or control risky early changes in certain mouth and throat lesions. You may be asked for small tissue samples (biopsies) before and after 12 weeks to see how the lesions respond.
Minneapolis, MinnesotaAges 18 years+ - NCT05726526Recruiting
Phone app monitoring to help people with advanced kidney disease
This study tests a phone app (with check-ins on things like blood pressure and weight) to help prevent complications in people with advanced chronic kidney disease. You may be a good match if you’re high risk and can actively measure and share your health data with a kidney care team.
Winnipeg, ManitobaAges 18 years+ - NCT05740111Enrolling by invitation
Watching early for pancreatic cancer in people at high risk
This study tests a personalized “watch and check” plan to help find pancreatic cancer as early as possible in people with a strong family history or certain inherited gene changes. It may help doctors tailor how often you’re monitored based on your risk.
OsloAges 30–80 - NCT05726292RecruitingPhase 2
Enzalutamide plus relacorilant versus placebo for high-risk prostate cancer
This study tests whether adding relacorilant to enzalutamide (a hormone-blocking treatment) helps control high-risk localized prostate cancer better than enzalutamide plus a dummy pill. It may help prevent the cancer from growing or spreading by targeting a hormone pathway in addition to standard treatment.
Chicago, IllinoisAges 18 years+ - NCT05650749Enrolling by invitationPhase 1
GPC2 car T cells for neuroblastoma and retinoblastoma
This trial tests a new treatment using engineered immune cells (CAR T cells) that target a protein called GPC2 found on some cancer cells. It is for patients with high-risk neuroblastoma or metastatic retinoblastoma that has returned or not responded to other treatments.
Philadelphia, PennsylvaniaAges 1 year+ - NCT05662462Recruiting
Phone coaching to keep blood sugar in range during pregnancy
This study tests whether technology plus coaching can help pregnant people with type 2 diabetes keep their blood sugar in a healthy target range. You may use a smartphone app and, if assigned to that group, a device that tracks glucose continuously.
Columbus, OhioAges 18 years+ - NCT05662696Recruiting
Telemonitoring for pregnant people at high risk of preeclampsia
This study tests whether a home telemonitoring program (sending health readings from home) is practical and helpful for people at high risk for preeclampsia. It may help catch warning signs earlier and support safer care during the first half of pregnancy.
Karachi, SindhAges 18 years+ - NCT05632380RecruitingPhase 1/Phase 2
Stem cell transplant with CAR-T therapy for high-risk myeloma
This study combines a stem cell transplant with a special immune therapy (CAR-T) to treat multiple myeloma that is very aggressive and has not responded well to initial treatments. The goal is to see if this combination can better control the cancer.
Tianjin, Tianjin MunicipalityAges 18–70 - NCT05620771RecruitingPhase 2
Y-90 radioembolization plus treatment for high-risk liver cancer
This Phase 2 trial tests TheraSphere® (a Y-90 radiation treatment delivered to the liver) combined with standard systemic therapy in people with high-risk hepatocellular carcinoma (HCC). It aims to shrink tumors and improve outcomes for people whose liver cancer is at higher risk to worsen.
Chicago, IllinoisAges 18 years+ - NCT05450432RecruitingPhase 4
Ketamine maintenance to help prevent suicidal thoughts
This Phase 4 study tests whether ongoing treatment with ketamine or esketamine can reduce suicidal thoughts in people with major depression who are at high risk. Because the study focuses on long-term maintenance, you’d receive treatment over time while being closely monitored for safety and mental health changes.
Boston, MassachusettsAges 18–70 - NCT05509998Recruiting
Improving early care for untreated psychosis
This trial looks at ways to help people get treatment sooner after psychosis starts. It focuses on how screening and better communication across care teams may reduce the time before treatment begins.
New York, New YorkAges 12–30 - NCT05040360RecruitingPhase 2
Chemotherapy after surgery for high-risk pancreatic NET tumors
This Phase 2 trial studies whether giving chemotherapy after surgery can lower cancer recurrence risk in people with high-risk pancreatic neuroendocrine tumors (NETs). It may help you by testing an added treatment after the tumor has been removed.
Anchorage, AlaskaAges 18 years+ - NCT05469893RecruitingPhase 2
Targeted treatment for high-risk smoldering myeloma
This trial studies a precision approach to treat people with high-risk smoldering myeloma (a condition that can turn into active myeloma). The goal is to see whether the treatment can slow or prevent progression and improve outcomes.
Denver, ColoradoAges 18 years+ - NCT05489887RecruitingPhase 2
Naxitamab with frontline chemotherapy for high-risk neuroblastoma
This Phase 2 trial tests whether adding a drug called naxitamab to standard early (frontline) treatment improves outcomes for children with high-risk neuroblastoma. It may help by helping the immune system better target the cancer during initial induction therapy.
Birmingham, AlabamaAges 1–21 - NCT05448547RecruitingPhase 3
Tested curative vs conservative treatment for older men with high-risk prostate cancer
This Phase 3 study compares an immediate curative treatment plan versus a more conservative approach in men age 75 and older with newly diagnosed, high-risk prostate cancer. The goal is to see which strategy controls the cancer while better protecting quality of life.
CopenhagenAges 75 years+
Hear when a new High Risk trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for high risk?
- Yes. Clin2 currently lists 922 recruiting high risk studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a high risk trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a high risk trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.